BeOne Medicines shared a post on LinkedIn:
“News for Investors and Media:
A late-breaking oral presentation will be presented at ASCO GI26 featuring a Phase 3 study evaluating a combination regimen including a HER2-targeted bispecific antibody that we have licensed in Asia Pacific (excluding Japan) with and without our PD-1 inhibitor in patients with HER2+ GEA.
Read the press release.”
Proceed to the video attached to the post.
More posts about ASCOGI26.